Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A biologically active VEGF construct in vitro: Implications for bioengineering-improved prosthetic vascular grafts
Autore:
Stone, D; Phaneuf, M; Sivamurthy, N; LoGerfo, FW; Quist, WC;
Indirizzi:
Beth Israel Deaconess Med Ctr, Vasc Surg Res Lab, Dept Surg, Div Vasc Surg, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr Boston MA USA 02115 g, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr, Dept Pathol, Vasc Surg Res Lab, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr Boston MA USA 02115 b, Boston, MA 02115 USA Harvard Univ, Childrens Hosp, Sch Med, Dept Cardiac Surg, Boston, MA 02115USA Harvard Univ Boston MA USA 02115 , Dept Cardiac Surg, Boston, MA 02115USA
Titolo Testata:
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
fascicolo: 1, volume: 59, anno: 2002,
pagine: 160 - 165
SICI:
0021-9304(200201)59:1<160:ABAVCI>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; RECOMBINANT HIRUDIN; SMALL-DIAMETER; COVALENT LINKAGE; BYPASS GRAFTS; ANGIOGENESIS; CELLS; PROLIFERATION; MECHANISMS; MIGRATION;
Keywords:
VEGF; bovine serum albumin; endothelial cells; biomaterials; crosslinkers;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Stone, D Beth Israel Deaconess Med Ctr, Vasc Surg Res Lab, Dept Surg, Div Vasc Surg, Harvard Inst Med Bldg,4 Blackfan Circle,Room 130, Boston, MA 02115 USA Beth Israel Deaconess Med Ctr Harvard Inst Med Bldg,4 Blackfan Circle,Room 130 Boston MA USA 02115
Citazione:
D. Stone et al., "A biologically active VEGF construct in vitro: Implications for bioengineering-improved prosthetic vascular grafts", J BIOMED MR, 59(1), 2002, pp. 160-165

Abstract

Prosthetic arterial grafts are unable to develop an intact endothelial lining after implantation, predisposing them to fail. Strategies have been sought to enhance endothelialization using growth factors and cytokines. This study assessed the biologic activity of vascular endothelial growth factor (VEGF) covalently linked to bovine serum albumin (BSA). Native and modifiedVEGF were assayed for endothelial cell migration and proliferation. Migration assays were performed comparing the effects of 2% fetal bovine serum (FBS), 50 ng/mL, 100 ng/mL, and 200 ng/mL of native VEGF and VEGF-BSA. Proliferation assays were performed by using Alamar Blue comparing cellular growth in 1% FBS, 10% FBS, 100 ng/mL unbound VEGF, and 100 ng/mL VEGF-BSA. VEGF is a potent chemotactic agent for endothelial cells in both unbound and bound states. Native VEGF solutions (50 ng/mL, 100 ng/mL, and 200 ng/mL) stimulated 23.9 cells/high power field (HPF), 35.3 cells/HPF, and 49.1 cells/HPF(12 < 0.005). VEGF-BSA solutions stimulated 25.9 cells/HPF, 39.1 cells/HPF, and 69.0 cells/HPF (p < 0.001). VEGF-BSA and native VEGF supported similar increased cellular proliferation compared with 1% FBS media (p < 0.002). Modified VEGF retains its chemotactic and proliferative properties in vitro. These findings suggest that bare prosthetic surfaces lined with VEGF bound to a "basecoat" albumin may support endothelial cell proliferation and migration and thereby offer new strategies to improve graft patency. (C) 2001John Wiley & Sons, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 00:06:33